- CannAssist International’s Xceptor Labs is active player within CBD-based product sector
- Global CBD product market is expected to rise in value from $4.6 billion in 2018 to over $23 billion by 2025
- Xceptor Labs differentiating product range through use, development of proprietary CiBiDinol technology
- CiBiDinol technology covers the oil soluble CBD molecule with a water soluble carrier thereby increasing its bioavailability and enabling easier absorption of product
- Xceptor Labs has recently launched its Xceptol product line, comprised of topical pain creams, CBD-derived capsules, tinctures and pet drops
CannAssist International (OTCQB: CNSC) is a biotechnological pharmaceutical and wellness company which has rapidly garnered a reputation and loyal following due to its innovative technology and proprietary product line, marketed through its Xceptol consumer brand. Founded in May 2017, CannAssist moved to the forefront of the cannabidiol industry following the passing of the 2018 Farm Bill, whereby the United States effectively decriminalized the cultivation and use of hemp and its derivative products. Since then, the global cannabidiol (“CBD”) industry has seen its growth and popularity surge to new heights, set to rise from a market value of $4.6 billion in 2018 to an estimated $23.6 billion by 2025 (https://ibn.fm/PL6PO).
In a sector which has seen its ranks rapidly swell given an influx of new entrants, CannAssist’s wholly owned Xceptor Labs has sought to differentiate itself through the use and development of its CiBiDinol technology. CiBiDinol technology is comprised of a proprietary process specifically designed to address a number of the shortcomings currently afflicting oil-soluble CBD molecules – namely, the delivery, bioavailability and short shelf-life (https://ibn.fm/GfbVM).
Through its unique formulations and technology, CannAssist has succeeded in developing CBD products offering a greater level of predictable potency while allowing for lower dosage requirements. By effectively covering the CBD molecule’s surface and rendering it water dispersible, CiBiDinol allows for more effective absorption of the product through the consumer’s skin and gut, which in turn significantly lowers the amount of CBD needed to achieve the product’s targeted endpoints.
Xceptor Labs has recently begun marketing its CiBiDinol technology-based Xceptol line of topical pain cream products as of September 2020. Comprising five creams which utilize FDA-registered ingredients and are designed to provide localized and fast-acting relief for sore and aching muscles and joints, the products are set to be sold online – through consumer products portal Range Me as well as through a network of international and domestic retail distributors. Meanwhile, the company is planning to raise awareness around the Xceptol product range through an upcoming series of targeted social media campaigns which will feature celebrities and former athletes advocating the product line’s various features. Xceptor Labs has recently added an array of CBD-based capsules, tinctures and pet drops.
CBD products have gained a reputation for their ability to provide medical relief under a variety of conditions while simultaneously excluding the psychoactive effects caused by tetrahydrocannabinol (“THC”). According to a study by the Harvard Health Institute in 2018, CBD products have been habitually used to address a wide gamut of health issues, including insomnia, anxiety, and physical pain, among various others. Meanwhile, increased legalization initiatives and growing consumer acceptance around the world have spurred further interest and innovation within the sector – a trend which CannAssist intends to lead.
Separately, CannAssist has recently revealed that based on the ongoing revenue trends from raw material and retail sales, and Xceptol’s international development, the company expects to generate sales of $5 million in first-year revenues.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
InvestorWire is part of the InvestorBrandNetwork.